Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis.

Abstract

PURPOSE:

To assess the effects of intravitreal bevacizumab injections in the treatment of juxtafoveal choroidal neovascularization associated with multifocal choroiditis.

METHODS:

Prospective interventional case series. Fourteen patients (14 eyes) affected by juxtafoveal choroidal neovascularization secondary to multifocal choroiditis were examined. All patients underwent a complete ophthalmologic examination, including measurement of best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography, and fluorescein angiography. The protocol treatment included a first injection, followed by repeated intravitreal bevacizumab injections over a 12-month follow-up period on the basis of optical coherence tomography parameters and angiographic features.

RESULTS:

Mean best-corrected visual acuity changed from 0.41 logarithm of the minimum angle of resolution (approximately corresponding to 20/51 Snellen equivalent), at baseline, to 0.16 ± 0.13 logarithm of the minimum angle of resolution (approximately corresponding to 20/28 Snellen equivalent), at the 12-month examination (P < 0.002). A functional improvement of at least 3 Early Treatment Diabetic Retinopathy Study lines was achieved by 6 eyes (43%) at the 12-month examination. Mean central macular thickness at baseline was 318 μm, reducing to 239 μm at the 12-month examination (P < 0.001). No eye showed choroidal neovascularization extension to the fovea.

CONCLUSION:

Intravitreal bevacizumab is a beneficial treatment for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Further studies are warranted to confirm these preliminary results.

• Authors: Maurizio B Parodi, Pierluigi Iacono, Ahamad Mansour, Umberto de Benedetto, Karl A Knutsson, Francesco Bandello, Focke Ziemssen, Thomas Ness, David Dodwell
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 33 Issue 5 Pg. 953-6 (May 2013) ISSN: 1539-2864 [Electronic] United States
• PMID: 23503338 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Adult
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Bevacizumab
• Choroidal Neovascularization (drug therapy, etiology, physiopathology)
• Choroiditis (complications, physiopathology)
• Female
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Prospective Studies
• Visual Acuity (physiology)